Supernus Pharmaceuticals, Inc. filed its Form 10-Q with the SEC on October 29, 2026, reporting financial results for the quarterly period ended September 30, 2026, including a return to net earnings in the third quarter after a net loss in the first half of the year.

Key Highlights

  • Q3 net earnings of $20.9 million: The company reported net earnings of $20,913 thousand for the three months ended September 30, 2026, compared to a net loss of $45,117 thousand in the same period of 2025.
  • Total Q3 revenues of $226.8 million: Total revenues for the three months ended September 30, 2026 were $226,771 thousand, up from $192,103 thousand in Q3 2025, according to the filing.
  • Collaboration revenue growth: Collaboration revenue (ZURZUVAE) was $41,697 thousand in Q3 2026, compared to $20,164 thousand in Q3 2025, as disclosed in the filing.
  • Nine-month net loss of $39.8 million: For the nine months ended September 30, 2026, the company reported a net loss of $39,751 thousand, versus a net loss of $34,445 thousand in the same period of 2025.
  • Impairment charges of $56.5 million year-to-date: The filing disclosed impairment charges of $56,460 thousand for the nine months ended September 30, 2026, with no comparable charges in the prior-year period.
  • Total assets of $1.40 billion: As of September 30, 2026, total assets were reported at $1,397,690 thousand, compared to $1,452,648 thousand at December 31, 2025.
  • Shares outstanding: As of October 27, 2026, the company reported 58,235,716 shares of common stock outstanding.

Supernus Pharmaceuticals Q3 2026 Financial Results: Revenue Growth and Return to Quarterly Profitability

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) disclosed its unaudited condensed consolidated financial results for the three and nine months ended September 30, 2026 in a Form 10-Q filed October 29, 2026. According to the filing, the company reported net earnings of $20,913 thousand for Q3 2026, a reversal from the net loss of $45,117 thousand reported in the third quarter of 2025. Diluted earnings per share for Q3 2026 were $0.35, compared to a diluted loss per share of $0.80 in Q3 2025.

Total revenues for the quarter reached $226,771 thousand, driven by net product sales of $178,576 thousand, collaboration revenue (ZURZUVAE) of $41,697 thousand, and royalty, licensing, and other revenues of $6,498 thousand, as the filing detailed. For the nine months ended September 30, 2026, total revenues were $653,534 thousand, compared to $507,380 thousand in the comparable prior-year period. The company reported that selling, general and administrative expenses for the nine-month period were $386,866 thousand, while research and development expenses were $94,657 thousand.

The filing also noted impairment charges of $56,460 thousand recorded during the first nine months of 2026, with no such charges in the corresponding 2025 period. Operating loss for the nine-month period was $45,116 thousand. On the balance sheet, total stockholders' equity was $1,062,478 thousand as of September 30, 2026, essentially flat compared to $1,061,714 thousand at December 31, 2025. Cash and cash equivalents stood at $175,884 thousand, up from $128,448 thousand at year-end 2025. Intangible assets, net, declined to $446,238 thousand from $569,456 thousand at December 31, 2025, reflecting the impairment charges and ongoing amortization disclosed in the filing.

What Was Disclosed

Supernus Pharmaceuticals filed its Q3 2026 Form 10-Q disclosing a return to net earnings in the quarter, year-to-date impairment charges of $56,460 thousand, growing collaboration revenue from ZURZUVAE, and a balance sheet with total assets of $1,397,690 thousand as of September 30, 2026.